Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 544 entries
Sorted by: Best Match Show Resources per page
New-onset diabetes mellitus in the kidney recipient: diagnosis and management strategies.

Clinical journal of the American Society of Nephrology : CJASN

Bloom RD, Crutchlow MF.
PMID: 18309002
Clin J Am Soc Nephrol. 2008 Mar;3:S38-48. doi: 10.2215/CJN.02650707.

Advancing care has markedly improved survival after kidney transplantation, leaving patients susceptible to the effects of chronic transplant-associated morbidities. New-onset diabetes mellitus (NODM) is common in kidney recipients, threatening health and longevity by predisposing to microvascular and cardiovascular disease...

Cite
Bloom RD, Crutchlow MF. New-onset diabetes mellitus in the kidney recipient: diagnosis and management strategies. Clin J Am Soc Nephrol. 2008;3:S38-48doi: 10.2215/CJN.02650707.
Bloom, R. D., & Crutchlow, M. F. (2008). New-onset diabetes mellitus in the kidney recipient: diagnosis and management strategies. Clinical journal of the American Society of Nephrology : CJASN, 3S38-48. https://doi.org/10.2215/CJN.02650707
Bloom, Roy D, and Crutchlow, Michael F. "New-onset diabetes mellitus in the kidney recipient: diagnosis and management strategies." Clinical journal of the American Society of Nephrology : CJASN vol. 3 (2008): S38-48. doi: https://doi.org/10.2215/CJN.02650707
Bloom RD, Crutchlow MF. New-onset diabetes mellitus in the kidney recipient: diagnosis and management strategies. Clin J Am Soc Nephrol. 2008 Mar;3:S38-48. doi: 10.2215/CJN.02650707. PMID: 18309002; PMCID: PMC3152270.
Copy Download .nbib Format: NLM
Gestational diabetes: pathogenesis and consequences to mother and offspring.

The review of diabetic studies : RDS

Kaaja R, Rönnemaa T.
PMID: 19290380
Rev Diabet Stud. 2008;5(4):194-202. doi: 10.1900/RDS.2008.5.194. Epub 2009 Feb 10.

Gestational diabetes mellitus (GDM) is defined as glucose intolerance with onset or first recognition during pregnancy. Data from Western countries suggest that the prevalence of GDM is increasing, being almost 10% of pregnancies and probably reflecting the global obesity...

Cite
Kaaja R, Rönnemaa T. Gestational diabetes: pathogenesis and consequences to mother and offspring. Rev Diabet Stud. 2009;5(4):194-202doi: 10.1900/RDS.2008.5.194.
Kaaja, R., & Rönnemaa, T. (2008). Gestational diabetes: pathogenesis and consequences to mother and offspring. The review of diabetic studies : RDS, 5(4), 194-202. https://doi.org/10.1900/RDS.2008.5.194
Kaaja, Risto, and Rönnemaa, Tapani. "Gestational diabetes: pathogenesis and consequences to mother and offspring." The review of diabetic studies : RDS vol. 5,4 (2008): 194-202. doi: https://doi.org/10.1900/RDS.2008.5.194
Kaaja R, Rönnemaa T. Gestational diabetes: pathogenesis and consequences to mother and offspring. Rev Diabet Stud. 2008;5(4):194-202. doi: 10.1900/RDS.2008.5.194. Epub 2009 Feb 10. PMID: 19290380; PMCID: PMC2664679.
Copy Download .nbib Format: NLM
Incretin-based therapies: new treatments for type 2 diabetes in the new millennium.

Therapeutics and clinical risk management

Khoo J, Rayner CK, Jones KL, Horowitz M.
PMID: 19707284
Ther Clin Risk Manag. 2009 Jun;5(3):683-98. doi: 10.2147/tcrm.s4975. Epub 2009 Aug 20.

The advent of 'incretin-based therapies' - GLP-1 agonists and dipeptidyl-peptidase-4 inhibitors - which result in improvements in glycemic control comparable to those with existing oral hypoglycemic agents, and potentially improve cardiovascular and pancreatic beta-cell function, represents a major therapeutic...

Cite
Khoo J, Rayner CK, Jones KL, et al. Incretin-based therapies: new treatments for type 2 diabetes in the new millennium. Ther Clin Risk Manag. 2009;5(3):683-98doi: 10.2147/tcrm.s4975.
Khoo, J., Rayner, C. K., Jones, K. L., & Horowitz, M. (2009). Incretin-based therapies: new treatments for type 2 diabetes in the new millennium. Therapeutics and clinical risk management, 5(3), 683-98. https://doi.org/10.2147/tcrm.s4975
Khoo, Joan, et al. "Incretin-based therapies: new treatments for type 2 diabetes in the new millennium." Therapeutics and clinical risk management vol. 5,3 (2009): 683-98. doi: https://doi.org/10.2147/tcrm.s4975
Khoo J, Rayner CK, Jones KL, Horowitz M. Incretin-based therapies: new treatments for type 2 diabetes in the new millennium. Ther Clin Risk Manag. 2009 Jun;5(3):683-98. doi: 10.2147/tcrm.s4975. Epub 2009 Aug 20. PMID: 19707284; PMCID: PMC2731024.
Copy Download .nbib Format: NLM
The oral hypoglycemics: boon or bane?.

Canadian family physician Medecin de famille canadien

Kenshole A.
PMID: 20469254
Can Fam Physician. 1975 Nov;21(11):57-9.

Following the UGDP study on oral hypoglycemic agents, and the Biometric Society's subsequent re-evaluation of the data, this form of therapy has been the subject of both attack and defence worldwide. This article reviews the basic findings of the...

Cite
Kenshole A. The oral hypoglycemics: boon or bane?. Can Fam Physician. 1975;21(11):57-9
Kenshole, A. (1975). The oral hypoglycemics: boon or bane?. Canadian family physician Medecin de famille canadien, 21(11), 57-9.
Kenshole, A. "The oral hypoglycemics: boon or bane?." Canadian family physician Medecin de famille canadien vol. 21,11 (1975): 57-9.
Kenshole A. The oral hypoglycemics: boon or bane?. Can Fam Physician. 1975 Nov;21(11):57-9. PMID: 20469254; PMCID: PMC2274765.
Copy Download .nbib Format: NLM
Understanding the cardiovascular effects of incretin.

Diabetes & metabolism journal

Yoon JS, Lee HW.
PMID: 22111033
Diabetes Metab J. 2011 Oct;35(5):437-43. doi: 10.4093/dmj.2011.35.5.437. Epub 2011 Oct 31.

Cardiovascular disease (CVD), a leading cause of death in patients with diabetes mellitus, has several pathogenic mechanisms that are well established. However, the traditional hypoglycemic agents do not have proven positive effects on macrovascular disease. Novel therapeutic agents target...

Cite
Yoon JS, Lee HW. Understanding the cardiovascular effects of incretin. Diabetes Metab J. 2011;35(5):437-43doi: 10.4093/dmj.2011.35.5.437.
Yoon, J. S., & Lee, H. W. (2011). Understanding the cardiovascular effects of incretin. Diabetes & metabolism journal, 35(5), 437-43. https://doi.org/10.4093/dmj.2011.35.5.437
Yoon, Ji Sung, and Lee, Hyoung Woo. "Understanding the cardiovascular effects of incretin." Diabetes & metabolism journal vol. 35,5 (2011): 437-43. doi: https://doi.org/10.4093/dmj.2011.35.5.437
Yoon JS, Lee HW. Understanding the cardiovascular effects of incretin. Diabetes Metab J. 2011 Oct;35(5):437-43. doi: 10.4093/dmj.2011.35.5.437. Epub 2011 Oct 31. PMID: 22111033; PMCID: PMC3221017.
Copy Download .nbib Format: NLM
Are proton pump inhibitors a new antidiabetic drug? A cross sectional study.

World journal of diabetes

Boj-Carceller D, Bocos-Terraz P, Moreno-Vernis M, Sanz-Paris A, Trincado-Aznar P, Albero-Gamboa R.
PMID: 22174957
World J Diabetes. 2011 Dec 15;2(12):217-20. doi: 10.4239/wjd.v2.i12.217.

AIM: To investigate the effect of proton pump inhibitors (PPIs) on glycemic control (HbA1c) in type 2 diabetic patients.METHODS: A cross-sectional study of consecutive in-patients admitted to hospital in any department during the first semester of the year 2010...

Cite
Boj-Carceller D, Bocos-Terraz P, Moreno-Vernis M, et al. Are proton pump inhibitors a new antidiabetic drug? A cross sectional study. World J Diabetes. 2011;2(12):217-20doi: 10.4239/wjd.v2.i12.217.
Boj-Carceller, D., Bocos-Terraz, P., Moreno-Vernis, M., Sanz-Paris, A., Trincado-Aznar, P., & Albero-Gamboa, R. (2011). Are proton pump inhibitors a new antidiabetic drug? A cross sectional study. World journal of diabetes, 2(12), 217-20. https://doi.org/10.4239/wjd.v2.i12.217
Boj-Carceller, Diana, et al. "Are proton pump inhibitors a new antidiabetic drug? A cross sectional study." World journal of diabetes vol. 2,12 (2011): 217-20. doi: https://doi.org/10.4239/wjd.v2.i12.217
Boj-Carceller D, Bocos-Terraz P, Moreno-Vernis M, Sanz-Paris A, Trincado-Aznar P, Albero-Gamboa R. Are proton pump inhibitors a new antidiabetic drug? A cross sectional study. World J Diabetes. 2011 Dec 15;2(12):217-20. doi: 10.4239/wjd.v2.i12.217. PMID: 22174957; PMCID: PMC3238490.
Copy Download .nbib Format: NLM
C-reactive protein is not correlated with endothelial dysfunction in overweight and obese women.

Journal of clinical medicine research

Sampaio RR, Ladeia AM, Meneses RB, Lima Mde L, Guimaraes AC.
PMID: 23864919
J Clin Med Res. 2013 Aug;5(4):294-9. doi: 10.4021/jocmr1418w. Epub 2013 Jun 21.

BACKGROUND: Obesity is a complex and multifactorial disease, has an inflammatory pattern and is associated with higher cardiometabolic risk. There are recent reports associating an elevated C-Reactive Protein (CRP) with a microscopic endothelial dysfunction. The objective is to evaluate...

Cite
Sampaio RR, Ladeia AM, Meneses RB, et al. C-reactive protein is not correlated with endothelial dysfunction in overweight and obese women. J Clin Med Res. 2013;5(4):294-9doi: 10.4021/jocmr1418w.
Sampaio, R. R., Ladeia, A. M., Meneses, R. B., Lima, M. d. e. . L., & Guimaraes, A. C. (2013). C-reactive protein is not correlated with endothelial dysfunction in overweight and obese women. Journal of clinical medicine research, 5(4), 294-9. https://doi.org/10.4021/jocmr1418w
Sampaio, Raphael Ribeiro, et al. "C-reactive protein is not correlated with endothelial dysfunction in overweight and obese women." Journal of clinical medicine research vol. 5,4 (2013): 294-9. doi: https://doi.org/10.4021/jocmr1418w
Sampaio RR, Ladeia AM, Meneses RB, Lima Mde L, Guimaraes AC. C-reactive protein is not correlated with endothelial dysfunction in overweight and obese women. J Clin Med Res. 2013 Aug;5(4):294-9. doi: 10.4021/jocmr1418w. Epub 2013 Jun 21. PMID: 23864919; PMCID: PMC3712885.
Copy Download .nbib Format: NLM
Latent autoimmune diabetes of adults: From oral hypoglycemic agents to early insulin.

Indian journal of endocrinology and metabolism

Poudel RR.
PMID: 22701843
Indian J Endocrinol Metab. 2012 Mar;16:S41-6. doi: 10.4103/2230-8210.94257.

Approximately 10% of phenotypic type 2 diabetics have islet autoantibodies and are referred to as having latent autoimmune diabetes of adults (LADA), and they land on early sulfonylurea failure and require insulin. Diagnosing LADA has treatment implications because of...

Cite
Poudel RR. Latent autoimmune diabetes of adults: From oral hypoglycemic agents to early insulin. Indian J Endocrinol Metab. 2012;16:S41-6doi: 10.4103/2230-8210.94257.
Poudel, R. R. (2012). Latent autoimmune diabetes of adults: From oral hypoglycemic agents to early insulin. Indian journal of endocrinology and metabolism, 16S41-6. https://doi.org/10.4103/2230-8210.94257
Poudel, Resham R. "Latent autoimmune diabetes of adults: From oral hypoglycemic agents to early insulin." Indian journal of endocrinology and metabolism vol. 16 (2012): S41-6. doi: https://doi.org/10.4103/2230-8210.94257
Poudel RR. Latent autoimmune diabetes of adults: From oral hypoglycemic agents to early insulin. Indian J Endocrinol Metab. 2012 Mar;16:S41-6. doi: 10.4103/2230-8210.94257. PMID: 22701843; PMCID: PMC3354922.
Copy Download .nbib Format: NLM
Glycemic Effects of Once-a-Day Rapid-Acting Insulin Analogue Addition on a Basal Insulin Analogue in Korean Subjects with Poorly Controlled Type 2 Diabetes Mellitus.

Diabetes & metabolism journal

Choe EY, Lee YH, Lee BW, Kang ES, Cha BS, Lee HC.
PMID: 22737663
Diabetes Metab J. 2012 Jun;36(3):230-6. doi: 10.4093/dmj.2012.36.3.230. Epub 2012 Jun 14.

BACKGROUND: The present study investigates the efficacy in glycemic control by adding once-a-day glulisine to glargine as a basal plus regimen and factors influencing glycemic control with the basal plus regimen in Korean subjects with type 2 diabetes.METHODS: In...

Cite
Choe EY, Lee YH, Lee BW, et al. Glycemic Effects of Once-a-Day Rapid-Acting Insulin Analogue Addition on a Basal Insulin Analogue in Korean Subjects with Poorly Controlled Type 2 Diabetes Mellitus. Diabetes Metab J. 2012;36(3):230-6doi: 10.4093/dmj.2012.36.3.230.
Choe, E. Y., Lee, Y. H., Lee, B. W., Kang, E. S., Cha, B. S., & Lee, H. C. (2012). Glycemic Effects of Once-a-Day Rapid-Acting Insulin Analogue Addition on a Basal Insulin Analogue in Korean Subjects with Poorly Controlled Type 2 Diabetes Mellitus. Diabetes & metabolism journal, 36(3), 230-6. https://doi.org/10.4093/dmj.2012.36.3.230
Choe, Eun Yeong, et al. "Glycemic Effects of Once-a-Day Rapid-Acting Insulin Analogue Addition on a Basal Insulin Analogue in Korean Subjects with Poorly Controlled Type 2 Diabetes Mellitus." Diabetes & metabolism journal vol. 36,3 (2012): 230-6. doi: https://doi.org/10.4093/dmj.2012.36.3.230
Choe EY, Lee YH, Lee BW, Kang ES, Cha BS, Lee HC. Glycemic Effects of Once-a-Day Rapid-Acting Insulin Analogue Addition on a Basal Insulin Analogue in Korean Subjects with Poorly Controlled Type 2 Diabetes Mellitus. Diabetes Metab J. 2012 Jun;36(3):230-6. doi: 10.4093/dmj.2012.36.3.230. Epub 2012 Jun 14. PMID: 22737663; PMCID: PMC3380127.
Copy Download .nbib Format: NLM
Ratio of fat to energy intake independently associated with the duration of diabetes and total cholesterol levels in type 2 diabetes.

Nutrition research and practice

Yim JE, Kim YS, Cho MR, Choue R.
PMID: 21556230
Nutr Res Pract. 2011 Apr;5(2):157-62. doi: 10.4162/nrp.2011.5.2.157. Epub 2011 Apr 25.

The importance of dietary intake in the treatment of type 2 diabetes was emphasized. This study was performed to investigate the dietary intakes of Korean type 2 diabetes patients according to the treatment and duration of diabetes and to...

Cite
Yim JE, Kim YS, Cho MR, et al. Ratio of fat to energy intake independently associated with the duration of diabetes and total cholesterol levels in type 2 diabetes. Nutr Res Pract. 2011;5(2):157-62doi: 10.4162/nrp.2011.5.2.157.
Yim, J. E., Kim, Y. S., Cho, M. R., & Choue, R. (2011). Ratio of fat to energy intake independently associated with the duration of diabetes and total cholesterol levels in type 2 diabetes. Nutrition research and practice, 5(2), 157-62. https://doi.org/10.4162/nrp.2011.5.2.157
Yim, Jung-Eun, et al. "Ratio of fat to energy intake independently associated with the duration of diabetes and total cholesterol levels in type 2 diabetes." Nutrition research and practice vol. 5,2 (2011): 157-62. doi: https://doi.org/10.4162/nrp.2011.5.2.157
Yim JE, Kim YS, Cho MR, Choue R. Ratio of fat to energy intake independently associated with the duration of diabetes and total cholesterol levels in type 2 diabetes. Nutr Res Pract. 2011 Apr;5(2):157-62. doi: 10.4162/nrp.2011.5.2.157. Epub 2011 Apr 25. PMID: 21556230; PMCID: PMC3085805.
Copy Download .nbib Format: NLM
Oral Hypoglycemic Agents in pregnancy: An Update.

Journal of obstetrics and gynaecology of India

Kavitha N, De S, Kanagasabai S.
PMID: 24431611
J Obstet Gynaecol India. 2013 Apr;63(2):82-7. doi: 10.1007/s13224-012-0312-z. Epub 2013 Mar 27.

INTRODUCTION: Traditionally, insulin has been the gold standard in the management of Type 2 diabetes in pregnancy and gestational diabetes. However, insulin therapy can be inconvenient because of the needs for multiple injections, its associated cost, pain at the...

Cite
Kavitha N, De S, Kanagasabai S. Oral Hypoglycemic Agents in pregnancy: An Update. J Obstet Gynaecol India. 2013;63(2):82-7doi: 10.1007/s13224-012-0312-z.
Kavitha, N., De, S., & Kanagasabai, S. (2013). Oral Hypoglycemic Agents in pregnancy: An Update. Journal of obstetrics and gynaecology of India, 63(2), 82-7. https://doi.org/10.1007/s13224-012-0312-z
Kavitha, Nagandla, et al. "Oral Hypoglycemic Agents in pregnancy: An Update." Journal of obstetrics and gynaecology of India vol. 63,2 (2013): 82-7. doi: https://doi.org/10.1007/s13224-012-0312-z
Kavitha N, De S, Kanagasabai S. Oral Hypoglycemic Agents in pregnancy: An Update. J Obstet Gynaecol India. 2013 Apr;63(2):82-7. doi: 10.1007/s13224-012-0312-z. Epub 2013 Mar 27. PMID: 24431611; PMCID: PMC3664692.
Copy Download .nbib Format: NLM
Ileal Interposition with Diverted sleeve gastrectomy for treatment of Type 2 diabetes.

Indian journal of endocrinology and metabolism

Kota SK, Ugale S, Gupta N, Krishna SV, Modi KD.
PMID: 23565466
Indian J Endocrinol Metab. 2012 Dec;16:S458-9. doi: 10.4103/2230-8210.104131.

OBJECTIVE: The objective of the present study was to prospectively evaluate the results of laparoscopic ileal interposition (II) with diverted sleeve gastrectomy (DSG) for control of type 2 diabetes mellitus (T2DM) and related metabolic abnormalities.MATERIALS AND METHODS: All patients...

Cite
Kota SK, Ugale S, Gupta N, et al. Ileal Interposition with Diverted sleeve gastrectomy for treatment of Type 2 diabetes. Indian J Endocrinol Metab. 2012;16:S458-9doi: 10.4103/2230-8210.104131.
Kota, S. K., Ugale, S., Gupta, N., Krishna, S. V., & Modi, K. D. (2012). Ileal Interposition with Diverted sleeve gastrectomy for treatment of Type 2 diabetes. Indian journal of endocrinology and metabolism, 16S458-9. https://doi.org/10.4103/2230-8210.104131
Kota, Sunil Kumar, et al. "Ileal Interposition with Diverted sleeve gastrectomy for treatment of Type 2 diabetes." Indian journal of endocrinology and metabolism vol. 16 (2012): S458-9. doi: https://doi.org/10.4103/2230-8210.104131
Kota SK, Ugale S, Gupta N, Krishna SV, Modi KD. Ileal Interposition with Diverted sleeve gastrectomy for treatment of Type 2 diabetes. Indian J Endocrinol Metab. 2012 Dec;16:S458-9. doi: 10.4103/2230-8210.104131. PMID: 23565466; PMCID: PMC3603114.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 544 entries